Efficacy and Safety of Efsubaglutide Alfa in Patients with Obesity or Overweight—A Phase 2 Study

Related

• A triple-target drug cut body weight by up to 19.7% in a trial

  Cell Metabolism · 8 Oct 2026

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• Retatrutide reduces weight and pain in adults with obesity

  The New England Journal of Medicine · 4 Oct 2026